AxoGen Revenue and Competitors
Estimated Revenue & Valuation
- AxoGen's estimated annual revenue is currently $83.9M per year.
- AxoGen received $41.0M in venture funding in November 2017.
- AxoGen's estimated revenue per employee is $205,225
- AxoGen's total funding is $69.9M.
Employee Data
- AxoGen has 409 Employees.
- AxoGen grew their employee count by 0% last year.
AxoGen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Area VP Sales - East | Reveal Email/Phone |
3 | Area VP, Director Sales for Europe, Northeast and Eastern United States | Reveal Email/Phone |
4 | Area VP, Director Sales for Europe, Northeast and Eastern United States | Reveal Email/Phone |
5 | EVP, General Counsel | Reveal Email/Phone |
6 | VP Regulatory Affairs | Reveal Email/Phone |
7 | VP Finance and Investor Relations | Reveal Email/Phone |
8 | VP, Marketing | Reveal Email/Phone |
9 | VP, Global Health Economics, Reimbursement and Policy | Reveal Email/Phone |
10 | VP and Corporate Controller | Reveal Email/Phone |
AxoGen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is AxoGen?
It's time to rethink nerve repair! AxoGen (NASDAQ: AXGN) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. People suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. Damage may cause loss of function and feeling. AxoGen is bringing the science of nerve repair to life with its Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft for bridging nerve discontinuities, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the healing process.
keywords:Biotechnology,E-Commerce,Healthcare,Medical Devices,Pharmaceuticals
$69.9M
Total Funding
409
Number of Employees
$83.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AxoGen News
Electromed (NYSE:ELMD) versus AxoGen (NASDAQ:AXGN) Critical Analysis. Posted by admin on Apr 18th, 2022. Share on Twitter Share on Facebook Share on...
AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves.
Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford bought 15,535 shares of AxoGen stock in a transaction that occurred on Monday, ...
Axogen is an elite partner for the meeting and will host a lunch symposium and panel discussion on Friday, September 6 from 12:00 – 1:00 p.m. ...
Other Companies in Alachua
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $146.6M | 584 | 1% | N/A |
AxoGen Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2006-03-03 | $7.8M | B | Springboard | Article |
| 2007-12-05 | $12.1M | C | Multiple | Article |
| 2009-09-21 | $2.6M | D | Article | |
| 2010-01-27 | $3.4M | Undisclosed | Article | |
| 2012-10-10 | $20.8M | Undiclosed | JMP Securities | Article |
| 2014-11-17 | $28.6M | Undisclosed | Oberland | Article |
| 2015-02-06 | $Undisclosed | Undisclosed | Article | |
| 2017-11-17 | $41.0M | Undisclosed | Leerink Partners | Article |